Abstract
Immune infiltration in tumors at baseline and association with response to T-DXd therapy. A, Tumoral CD8+ cell densities, as determined using mIHC, at baseline in responders and nonresponders. B, CD8A and CD8B mRNA expression levels, as determined using RNA-seq, in responders and nonresponders. CPM, counts per million. C, Relationship between immune cell densities for cells expressing CD4, CD68, CD20, CD163, CD208, and CD1a, as determined using mIHC and IHC. D, Relationship between immune cell densities and T-DXd efficacy. Patients with high vs. low immune cell densities were grouped based on the median value.